Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia
Status:
Terminated
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to evaluate the dose response relationship of lonidamine and the
primary efficacy endpoint, International Prostate Symptom Score (IPSS), in subjects with
symptomatic benign prostatic hyperplasia (BPH).